Introduction Purpose This paper seeks to address the sharp increase in the use of psychotropic medications among children. The paper will review various articles to analyze the contributing factors based on the pediatric psychopharmacology literature that explores the increased awareness of various health issues among children and the establishment of intervention measures that are viewed as safer as compared to that of adults. This paper will also evaluate controversies in clinical management to establish the way forward to finding sustainable solutions and make recommendations. Significance The current trends in the field of medicine have been purely evidence-based, thus, compelling health practitioners and child welfare advocates to involve in a keen assessment of the danger and significance of applying psychopharmacological interventions in young children. Much attention on this issue has accumulated, thus, causing a strong wave of curiosity and confusion. This attention seeks to identify if the ongoing application of psychotropic products is undertaken appropriately to eliminate bad impulses and feelings among children. The proper use of these treatments should consider potential effects on neurological growth, personality development, and behavior (Alavi & Calleja, 2012). However, suspicions persist that this pattern may be facilitated by a profit-induced demand generated by drug companies and unscrupulous medical practitioners. Despite the increased awareness about the use of psychotropic drugs in the United States, cases of overuse of such medications among children persist. This clinical misappropriation has the potential of exacerbating careless or hazardous treatments and lead to unwanted health care costs. Meanwhile, the prescription of psychotropic drugs to reduce emotional and behavioral challenges among children in the U.S has been on the rise in the recent past. These medications have been used widely to treat children with mental problems. However, studies indicate that when applied properly, psychotropic medications can be very beneficial (Huefner & Griffith, 2014). On the other hand, the overuse of such drugs has proved detrimental to young children regarding severe side effects. Unfortunately, today, most young patients receive medications without being assessed using evidence-based procedures. Most Americans visit their physicians and receive medications without being evaluated using cognitive behavioral therapy that might be effective. This trend can be linked to the low level of collaboration between mental health care workers and the patient population. Following the increased awareness of critical mental health challenges among children, society has increased its expectations based on the improved experience of practitioners. Even though this field has made profound progress in managing adverse psychiatric problems amongst young children, relying solely on pharmacological interventions might worsen the situation. Thus, the need for an evidence-based and thoughtful plan for the application of psychotropic drugs with young children is inevitable. During a review of advancements in pediatric psychopharmacology, Shelton, Ehret, Wakai, Kapetanovic, and Moran (2010) identified that psychiatric problems are likely to be more pronounced and unresponsi